Omeros
Omeros Corporation is an American multinational commercial-stage biopharmaceutical enterprise specializing in the discovery, research, clinical development, and global wholesale distribution of innovative small-molecule therapeutics, protein biologics, and targeted immunologic drugs focusing on complement-mediated diseases, disorders of the central nervous system, and targeted oncological indications, prominently featuring commercial ophthalmology products (such as Omidria) distributed across the United States and international markets. Operating advanced R&D laboratories and clinical development centers in Seattle, Washington, the company pioneers breakthrough immunologic and neurological medicines. Its core business operations encompass biopharmaceutical drug discovery, clinical trial management, pharmaceutical manufacturing partnerships, and commercial drug wholesale distribution. Revenue is derived primarily from commercial product sales of ophthalmic therapeutics, milestone payments, and biopharmaceutical licensing agreements. Omeros holds an established market position in complement-targeted therapeutics and clinical biopharmaceuticals. The company is headquartered in Seattle, Washington, United States, and its common stock trades on the Nasdaq Global Market under the ticker OMER.
2 of the funds FundTelligence covers report a position in Omeros.
- Legal name
- Omeros Corp
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Omeros
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.08 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)